{
    "data": [
        {
            "id": "4659359",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-23T04:18:53-05:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1432338461/image_1432338461.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Vs. GSK: Dual Dominance In Pharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "107221",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "510807",
                            "type": "sentiment"
                        },
                        {
                            "id": "510808",
                            "type": "sentiment"
                        },
                        {
                            "id": "510810",
                            "type": "sentiment"
                        },
                        {
                            "id": "510809",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4659359-abbvie-vs-gsk-dual-dominance-in-pharma"
            }
        },
        {
            "id": "4655595",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-03T17:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 45,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/467307789/image_467307789.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: 4 Hidden Keys Investors Must Know To Judge ImmunoGen Acquisition",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106171",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "506362",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4655595-abbvie-4-hidden-keys-investors-must-know-to-judge-immunogen-acquisition"
            }
        },
        {
            "id": "4655539",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-02T02:24:45-05:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307666845/image_1307666845.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Risky Purchase Of ImmunoGen Could Pay Off Big Time",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "69675",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "506221",
                            "type": "sentiment"
                        },
                        {
                            "id": "506222",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4655539-abbvie-risky-purchase-immunogen-pay-off-big-time"
            }
        },
        {
            "id": "4655486",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-01T16:26:19-05:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1192776052/image_1192776052.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: $10 Billion Cancer Deal To Boost Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "506156",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4655486-abbvie-10-billion-cancer-deal-to-boost-growth"
            }
        },
        {
            "id": "4655261",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-30T16:03:03-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445681409/image_1445681409.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Bets Big On ImmunoGen: A $10 Billion Leap Into Ovarian Oncology",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103833",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "505881",
                            "type": "sentiment"
                        },
                        {
                            "id": "505882",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4655261-abbvie-bets-big-on-immunogen-a-ten-billion-dollar-leap-into-ovarian-oncology"
            }
        },
        {
            "id": "4655255",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-30T15:10:23-05:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1443177554/image_1443177554.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie's $10bn Deal For ImmunoGen: Fundamentals And Rationale Explained",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "505906",
                            "type": "sentiment"
                        },
                        {
                            "id": "505907",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4655255-abbvie-10bn-deal-for-immunogen-fundamentals-and-rationale-explained"
            }
        },
        {
            "id": "4655103",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-30T09:45:00-05:00",
                "isLockedPro": false,
                "commentCount": 38,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/482499870/image_482499870.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Get Ready For More Painful Downside",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "505761",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4655103-abbvie-get-ready-for-more-painful-downside"
            }
        },
        {
            "id": "4655063",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-29T23:45:45-05:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1661674291/image_1661674291.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Collect Growing Passive Income From This Dividend Aristocrat (Rating Upgrade)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104980",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "505570",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4655063-abbvie-stock-collect-growing-passive-income-dividend-aristocrat-upgrade-buy"
            }
        },
        {
            "id": "4654945",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-29T14:12:09-05:00",
                "isLockedPro": false,
                "commentCount": 42,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307666845/image_1307666845.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy The Dip In AbbVie? Nope, Not This Time",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "39011",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "505504",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4654945-buy-the-dip-in-abbvie-nope-not-this-time"
            }
        },
        {
            "id": "4654889",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-29T11:10:12-05:00",
                "isLockedPro": false,
                "commentCount": 36,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1209562710/image_1209562710.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "4.5%-Yielding AbbVie Is One Of My Favorite Value Plays For 2024",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "92986",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "505500",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4654889-4-5-percent-yielding-abbvie-is-one-of-my-favorite-value-plays-for-2024"
            }
        },
        {
            "id": "4653426",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-21T11:53:00-05:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1455774438/image_1455774438.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Vs. Amgen: How Peter Lynch Picks Dividend Stocks",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "503736",
                            "type": "sentiment"
                        },
                        {
                            "id": "503737",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4653426-abbvie-vs-amgen-how-peter-lynch-picks-dividend-stocks"
            }
        },
        {
            "id": "4644925",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-30T01:41:31-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1454143553/image_1454143553.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Stock Still A Hold Despite Positive Third Quarter 2023 Results",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "497493",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4644925-abbvie-stock-still-hold-despite-positive-q3-2023-results"
            }
        },
        {
            "id": "4642588",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-23T09:10:13-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307666845/image_1307666845.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Q3 Earnings Preview: Tough Comparison For Humira Shouldn't Derail Growth Plans",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "495787",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4642588-abbvie-q3-earnings-preview-tough-comparison-humira-shouldnt-derail-growth-plans"
            }
        },
        {
            "id": "4641497",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-18T11:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1485941589/image_1485941589.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: The Humira Loss May Be Fully Priced In After All",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106485",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "494132",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4641497-abbvie-the-humira-loss-may-be-fully-priced-in-after-all"
            }
        },
        {
            "id": "4641341",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-17T13:58:45-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307666850/image_1307666850.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Q2 Success Sets The Stage For Consistent Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106842",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "493982",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4641341-abbvie-q2-success-sets-the-stage-for-consistent-growth"
            }
        },
        {
            "id": "4641259",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-17T09:20:17-04:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1257405518/image_1257405518.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Why You Should Pay Attention To This High-Yielding Dividend King (Rating Downgrade)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104980",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "493904",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4641259-abbvie-why-you-should-pay-attention-to-this-high-yielding-dividend-king-rating-downgrade"
            }
        },
        {
            "id": "4641119",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-16T17:48:42-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307666845/image_1307666845.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Q3 Preview: Humira Weakness Is A Given But Watch The New Drugs",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25319",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "493797",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4641119-abbvie-q3-preview-humira-weakness-is-a-given-but-watch-the-new-drugs"
            }
        },
        {
            "id": "4641021",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-16T10:44:28-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307666845/image_1307666845.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Successfully Navigating Humira's Patent Cliff With 4% Yield And 270% DGR Since 2014",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "107131",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "493672",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4641021-abbvie-successfully-navigating-humira-patent-cliff-with-4-percent-yield-and-270-percent-dgr-since-2014"
            }
        },
        {
            "id": "4635783",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-18T11:08:15-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1440458156/image_1440458156.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Company Vs. Stock, A Gentle Facelift Would Be Nice (Technical Analysis)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105252",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "486455",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4635783-abbvie-company-vs-stock-gentle-facelift-technical-analysis"
            }
        },
        {
            "id": "4635454",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-15T13:02:18-04:00",
                "isLockedPro": false,
                "commentCount": 20,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/648736516/image_648736516.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Vs. AstraZeneca: Battle Of The Pharmaceutical Behemoths",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "486122",
                            "type": "sentiment"
                        },
                        {
                            "id": "486123",
                            "type": "sentiment"
                        },
                        {
                            "id": "486124",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4635454-abbvie-vs-astrazeneca-battle-of-the-pharmaceutical-behemoths"
            }
        },
        {
            "id": "4632906",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-04T12:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 53,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1392050440/image_1392050440.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Proving The Bears Wrong Again As Shares Surged",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "482998",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4632906-abbvie-proving-the-bears-wrong-again-as-shares-surged"
            }
        },
        {
            "id": "4632926",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-04T08:19:59-04:00",
                "isLockedPro": false,
                "commentCount": 49,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/668600179/image_668600179.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Unleashed: 4% Yield, Potentially 40% Undervalued",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "92986",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "483011",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4632926-abbvie-unleashed-4-percent-yield-potentially-40-percent-undervalued"
            }
        },
        {
            "id": "4632865",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-04T01:12:08-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/869181596/image_869181596.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Balance Is Everything",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105284",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "482975",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4632865-abbvie-stock-balance-drugs-everything"
            }
        },
        {
            "id": "4630641",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-23T16:06:50-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307666845/image_1307666845.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Still A Buy According To Buffett's 10xEBT Rule",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "480577",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4630641-abbvie-still-a-buy-according-to-buffett-10xebt-rule"
            }
        },
        {
            "id": "4623556",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-03T17:48:09-04:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1422564173/image_1422564173.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Labs Vs AbbVie: Which One Is The Best Investment Choice?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "82056",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "475641",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4623556-abbott-labs-vs-abbvie-which-one-is-the-best-investment-choice"
            }
        },
        {
            "id": "4621123",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-28T12:20:14-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1454448091/image_1454448091.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Unveiling AbbVie's Hidden Risks: Cautionary Notes For Investors",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "474031",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4621123-unveiling-abbvies-hidden-risks-cautionary-notes-for-investors"
            }
        },
        {
            "id": "4619482",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-25T09:00:30-04:00",
                "isLockedPro": false,
                "commentCount": 32,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1382270658/image_1382270658.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Q2 2023 Earnings Preview: Pharma Faces Toughest Test, Street Demands Answers",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "473183",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4619482-abbvie-q2-earnings-preview-pharma-faces-toughest-test-street-demands-answers"
            }
        },
        {
            "id": "4617664",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-21T14:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 35,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1456508924/image_1456508924.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Loss Of Exclusivity Is A Natural End Process",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106485",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "470995",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4617664-abbvie-stock-loss-of-exclusivity-natural-end-process"
            }
        },
        {
            "id": "4617891",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-19T10:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 82,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1030798828/image_1030798828.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Dancing On Humira's Grave",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106588",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "471371",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4617891-abbvie-dancing-on-humiras-grave"
            }
        },
        {
            "id": "4617197",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-14T16:54:37-04:00",
                "isLockedPro": false,
                "commentCount": 72,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1374841003/image_1374841003.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "More Challenges Await AbbVie Following A Disappointing Quarter",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "470701",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4617197-more-challenges-await-abbvie-following-a-disappointing-quarter"
            }
        },
        {
            "id": "4615656",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-07T07:30:18-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1392050440/image_1392050440.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Humira Overhang Is A Fantastic Buying Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "468823",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4615656-abbvie-stock-humira-overhang-fantastic-buying-opportunity"
            }
        },
        {
            "id": "4615682",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-07T05:58:04-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418835107/image_1418835107.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: A Buy Despite Declining Humira Sales",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102404",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "468811",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4615682-abbvie-abbv-buy-despite-declining-humira-sales"
            }
        },
        {
            "id": "4615472",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-06T08:50:06-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307666844/image_1307666844.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: 'Hold' In The Short Term, 'Buy' On Humira-Inspired Dips",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103833",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "468558",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4615472-abbvie-hold-in-the-short-term-buy-on-humira-inspired-dips"
            }
        },
        {
            "id": "4615441",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-06T08:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1312231371/image_1312231371.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Use This Buying Opportunity (Rating Upgrade)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "468498",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4615441-abbvie-use-this-buying-opportunity-rating-upgrade"
            }
        },
        {
            "id": "4611928",
            "type": "article",
            "attributes": {
                "publishOn": "2023-06-16T07:54:01-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307666845/image_1307666845.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: A Pharmaceutical Powerhouse Despite Humira Challenges",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106302",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "464021",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4611928-abbvie-pharmaceutical-powerhouse-despite-humira-challenges"
            }
        },
        {
            "id": "4609482",
            "type": "article",
            "attributes": {
                "publishOn": "2023-06-05T13:00:02-04:00",
                "isLockedPro": false,
                "commentCount": 69,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1435303542/image_1435303542.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Stock May Be Falling On Humira LOE - But Investors Shouldn't Panic",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "461283",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4609482-abbvie-stock-falling-humira-loe-investors-shouldnt-panic"
            }
        },
        {
            "id": "4606259",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-21T17:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 74,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1396139907/image_1396139907.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The AbbVie Update: Q1 Spotlight On Life After Humira",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106171",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "457592",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4606259-the-abbvie-update-q1-spotlight-on-life-after-humira"
            }
        },
        {
            "id": "4602462",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-10T10:22:36-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1088402038/image_1088402038.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: A Rise In The Incidence Of IBD Could Boost Profits",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105052",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "455215",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4602462-abbvie-a-rise-in-the-incidence-of-ibd-could-boost-profits"
            }
        },
        {
            "id": "4601865",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-09T06:40:15-04:00",
                "isLockedPro": false,
                "commentCount": 72,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1131216270/image_1131216270.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Or Johnson & Johnson? Let's Ask Peter Lynch",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "454915",
                            "type": "sentiment"
                        },
                        {
                            "id": "454916",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4601865-abbvie-or-johnson-and-johnson-lets-ask-peter-lynch"
            }
        },
        {
            "id": "4599169",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-03T07:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 49,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307666845/image_1307666845.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Sells Off, I Am Buying",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "92986",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "453637",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4599169-abbvie-stock-sells-off-post-q1-earnings-i-am-buying"
            }
        },
        {
            "id": "4599306",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-03T07:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1314630762/image_1314630762.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Versus AbbVie: The Better Bet After Q1, 2023 Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101378",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "453149",
                            "type": "sentiment"
                        },
                        {
                            "id": "453150",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4599306-gilead-gild-versus-abbvie-abbv-better-bet-after-q1-2023-earnings"
            }
        },
        {
            "id": "4597953",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-28T18:25:06-04:00",
                "isLockedPro": false,
                "commentCount": 63,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1167582826/image_1167582826.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What To Expect After The Failed AbbVie Drug Sales",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "452783",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4597953-what-to-expect-after-the-failed-abbvie-drug-sales"
            }
        },
        {
            "id": "4597360",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-27T14:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 60,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307666844/image_1307666844.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Time To Sound The Warning Bells For AbbVie?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103599",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "452620",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4597360-time-to-sound-the-warning-bells-for-abbvie"
            }
        },
        {
            "id": "4596013",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-24T10:58:22-04:00",
                "isLockedPro": false,
                "commentCount": 39,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1332376463/image_1332376463.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Q1 2023 Earnings Preview: All Eyes On Humira - I'm Expecting A Beat",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "451756",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4596013-abbvie-q1-earnings-preview-all-eyes-on-humira-expecting-beat"
            }
        },
        {
            "id": "4595994",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-24T09:00:12-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1320297841/image_1320297841.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Stock Q1 Earnings Preview: What To Watch For",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101378",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "451109",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4595994-abbvie-stock-q1-earnings-preview-what-to-watch"
            }
        },
        {
            "id": "4594024",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-15T07:35:00-04:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307666845/image_1307666845.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: An Investor's Trifecta In Transition",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103599",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "449805",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4594024-abbvie-stock-investors-trifecta-in-transition"
            }
        },
        {
            "id": "4593989",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-13T17:26:40-04:00",
                "isLockedPro": false,
                "commentCount": 162,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307666845/image_1307666845.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: The Tsunami Heading Towards Investors",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105667",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "449758",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4593989-abbvie-the-tsunami-heading-towards-investors"
            }
        },
        {
            "id": "4593950",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-13T14:08:13-04:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1392050440/image_1392050440.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Less Attractive Following The Run-Up",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "449719",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4593950-abbvie-stock-less-attractive-following-run-up"
            }
        },
        {
            "id": "4587321",
            "type": "article",
            "attributes": {
                "publishOn": "2023-03-14T12:43:03-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1392050440/image_1392050440.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Comparing The Current Valuation To Its Last Growth Cycle",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106667",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "443679",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4587321-abbvie-comparing-current-valuation-to-last-growth-cycle"
            }
        },
        {
            "id": "4587272",
            "type": "article",
            "attributes": {
                "publishOn": "2023-03-14T10:31:38-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1332376463/image_1332376463.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: A 4% SWAN Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25319",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "443517",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4587272-abbvie-4-percent-swan-stock"
            }
        },
        {
            "id": "4587223",
            "type": "article",
            "attributes": {
                "publishOn": "2023-03-14T07:44:19-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1325872227/image_1325872227.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Weather The Fed With AbbVie's Strong Portfolio And Solid Dividend Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103282",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "443669",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4587223-weather-the-fed-with-abbvies-strong-portfolio-and-solid-dividend-growth"
            }
        },
        {
            "id": "4587174",
            "type": "article",
            "attributes": {
                "publishOn": "2023-03-14T03:17:24-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1067598518/image_1067598518.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: With Banks In Distress, Look At Recession-Resilient Healthcare Companies",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102404",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "443569",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4587174-abbvie-stock-dividend-yield-higher-growth-potential-buy"
            }
        },
        {
            "id": "4586979",
            "type": "article",
            "attributes": {
                "publishOn": "2023-03-13T17:00:14-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1401290962/image_1401290962.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is AbbVie Stock Safe In A Jittery Market?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106171",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "443454",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4586979-is-abbvie-stock-safe-in-jittery-market"
            }
        },
        {
            "id": "4577834",
            "type": "article",
            "attributes": {
                "publishOn": "2023-02-13T12:33:52-05:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1332376463/image_1332376463.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is AbbVie Stock A Buy After Earnings? Consider Revenue Outlook And Valuations",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "39591",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "437344",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4577834-is-abbvie-stock-buy-after-earnings"
            }
        },
        {
            "id": "4577351",
            "type": "article",
            "attributes": {
                "publishOn": "2023-02-10T13:00:30-05:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307666845/image_1307666845.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: A 4% Yield Plus Potential Upside - What's Not To Like?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53262",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "437002",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4577351-abbvie-a-4-percent-yield-plus-potential-upside-whats-not-to-like"
            }
        },
        {
            "id": "4575703",
            "type": "article",
            "attributes": {
                "publishOn": "2023-02-06T16:48:16-05:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1392050440/image_1392050440.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Wall Street Analysts And Options Market Suggest AbbVie Has Upside",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20102",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "436188",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4575703-wall-street-analysts-and-options-market-suggest-abbvie-has-upside"
            }
        },
        {
            "id": "4575487",
            "type": "article",
            "attributes": {
                "publishOn": "2023-02-06T07:30:00-05:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1392050440/image_1392050440.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is AbbVie A Buy Following The Share Price Slump?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "435835",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4575487-is-abbvie-stock-buy-following-share-price-slump"
            }
        },
        {
            "id": "4575440",
            "type": "article",
            "attributes": {
                "publishOn": "2023-02-05T17:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 103,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1357334701/image_1357334701.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: The Dreaded Humira Cliff Is Here: Time To Sell?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106171",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "435809",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4575440-abbvie-dreaded-humira-cliff-here-time-to-sell"
            }
        },
        {
            "id": "4573349",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-29T05:42:31-05:00",
                "isLockedPro": false,
                "commentCount": 76,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1366228042/image_1366228042.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Why The Company Is Still Overvalued",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "434363",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4573349-abbvie-why-the-company-is-still-overvalued"
            }
        },
        {
            "id": "4571271",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-20T14:14:58-05:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1430435347/image_1430435347.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Better 2023 Dividend Stock: AbbVie Or Johnson & Johnson?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "432666",
                            "type": "sentiment"
                        },
                        {
                            "id": "432667",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4571271-better-2023-dividend-stock-abbvie-or-johnson-and-johnson"
            }
        },
        {
            "id": "4570975",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-19T13:31:09-05:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1132310009/image_1132310009.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Modelling The Post Humira Bull Case To 2030 - The Outlook Is Bright",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "432478",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4570975-abbvie-modelling-post-humira-bull-case-2030-bright-outlook"
            }
        },
        {
            "id": "4570462",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-17T20:05:57-05:00",
                "isLockedPro": false,
                "commentCount": 140,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1317087986/image_1317087986.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie : To Buy Or Not To Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "91485",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "431343",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4570462-abbvie-abbv-stock-to-buy-not-to-buy"
            }
        },
        {
            "id": "4568215",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-06T09:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1294430708/image_1294430708.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott And AbbVie: 10 Years Of Blue Chip Outperformance, More To Come",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101378",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "429160",
                            "type": "sentiment"
                        },
                        {
                            "id": "429161",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4568215-abbott-abbvie-stock-fully-priced-despite-challenges-hold"
            }
        },
        {
            "id": "4567899",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-06T07:15:00-05:00",
                "isLockedPro": false,
                "commentCount": 76,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/520885672/image_520885672.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Vs. AbbVie: The Better Dividend Aristocrat Buy Might Shock You",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "429396",
                            "type": "sentiment"
                        },
                        {
                            "id": "429397",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4567899-johnson-and-johnson-vs-abbvie-the-better-dividend-aristocrat-buy-might-shock-you"
            }
        },
        {
            "id": "4567258",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-01T08:29:55-05:00",
                "isLockedPro": false,
                "commentCount": 43,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1315874644/image_1315874644.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To Benefit",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "81956",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "428745",
                            "type": "sentiment"
                        },
                        {
                            "id": "428746",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4567258-2023-big-year-testosterone-abbvie-ani-best-positioned-to-benefit"
            }
        }
    ]
}